Figure 5.

Venetoclax enhances the sensitivity of leukemia cells to sorafenib: (a–c) The proliferation rate of Jurkat (a), MOLM13 (b), and K562 cells (c) with sorafenib and/or venetoclax treatments as indicated. (d–f) The representative FACS plots (left) and apoptosis rate (right) of Jurkat (d), MOLM13 (e), and K562 cells (f) with indicated in vitro treatment for 48 h (n = 3 independent experiments). (g–i) Western blots and quantification of the cleaved caspase 3 in Jurkat (g), MOLM13 (h), and K562 (i) cells received sorafenib (1 μM) and/or venetoclax (1 μM) treatments as indicated. β-actin was used as a loading control. SF, sorafenib; Vene, venetoclax. ns: no significance.